Drug Profile
Apomorphine intranasal - ProStrakan
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Archimedes Pharma
- Developer ProStrakan
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 31 Mar 2016 No recent reports on development identified - Phase-I for Parkinson's disease (In volunteers) in United Kingdom (Intranasal)
- 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan